Scout DS® Diabetes Screen

home_pic_03

The Scout DS® is a ground-breaking new diabetes-screening device that uses visible light to fluoresce, detect and measure biomarkers present in the skin associated with pre-diabetes and type 2 diabetes. Diabetes is a serious health condition of elevated blood sugars where the body does not produce enough insulin to meet the body’s needs, or the body does not respond properly to the insulin being made. Insulin is critical as it moves glucose into the body’s cells from the blood. Complications from diabetes can include blindness, heart disease, stroke, kidney disease, nerve damage, and erectile dysfunction.

The skin contains proteins with sugar molecules attached to them called Advanced Glycation End-Products (AGE’s) that form as we age, but there are more of them present when we can’t process blood sugars properly. In short, they fluoresce when excited by specific light waves emitted by the Scout DS® device, and this is then detected by the device’s sophisticated sensor apparatus and captured by its camera. Research studies with Scout DS® have measured over 15,000 individuals and commercial screening has been done on over 5,000 people

The Scout DS® painlessly scans a patient’s skin for AGE’s – along with a series of other key biomarkers – and then generates a numerical result after running more than 200 data points through a complex and proprietary algorithm that determines one’s level of risk for pre-diabetes or type 2 diabetes based on all the clinical studies that have been done. Individuals with elevated test result are then recommended to follow-up with their physicians for confirmatory blood testing. The process can take as little as 90 seconds to complete and doesn’t involve the use of needles, blood work, lengthy wait times, fasting, or an initial appointment with one’s physician. It’s completely non-invasive, with patients conveniently and painlessly placing their forearm on the Scout DS®device, and it is the only effective and highly-sensitive non-invasive screening technology available for diabetes risk assessment in the world.

The Scout DS® is Health Canada cleared, CE-Marked for the EU (compliant with European Union legislation), and the company plans to file pre-submission documentation with the United States Food and Drug Administration (FDA) regarding the de novo classification of the Scout DS® as a next step in securing a marketing clearance pathway in the United States.

For further information about the Scout DS® please visit www.thescoutds.com